B
BDTX
Black Diamond Therapeutics, Inc.
2.39
0.06+2.58%After Hours: 2.400 +0.010 +0.42%19:40 04/02 EDT
OPEN/PREV CLOSE2.290/2.330
TODAY RANGE2.280-2.490
VOL535.68K
MARKET CAP136.92M
52 WEEK RANGE1.195-4.940
AVG VOL (3M)727.07K
% TURNOVER0.94%
TURNOVER--
P/E (TTM)6.15
% RANGE9.01%
EPS(TTM)0.3886
P/E(FORWARD)-3.1867
P/B1.217
BVPS1.964
DIVIDEND--
P/S1.951
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP135.64M
SHARES OUTSTANDING57.29M
NEXT EARNINGS05/11-05/15
FREE FLOAT56.75M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·03/25 12:53
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity
Simply Wall St·03/18 02:15
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives
Dow Jones·03/17 12:45
Black Diamond Theraptcs Is Maintained at Outperform by Wedbush
Dow Jones·03/17 12:45
Black Diamond Theraptcs Price Target Raised to $14.00/Share From $13.00 by Wedbush
TipRanks·03/17 11:51
Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush
TipRanks·03/17 11:35
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)
TipRanks·03/17 11:15
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
TipRanks·03/17 03:25
Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen
Seeking Alpha·03/16 21:00
Black Diamond Therapeutics GAAP EPS of -$0.27 misses by $0.09
TipRanks·03/16 20:05
Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)
Benzinga·03/16 20:04
Black Diamond Therapeutic Q4 EPS $(0.27) Misses $(0.19) Estimate
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.